WFDC16 Inhibitors
WFDC16 inhibitors refer to a class of chemical compounds that specifically interact with and inhibit the activity of a protein known as WAP Four-Disulfide Core Domain 16 (WFDC16). This protein is part of a larger family of WFDC proteins, which are characterized by having at least one WAP domain. The WAP domain is a conserved protein domain containing eight cysteine residues that form four disulfide bonds, thus the name 'four-disulfide core'. These domains are critical for the structural stability and function of the proteins they compose. WFDC16 itself, like other members of its family, is a small, secreted protein with one or more WAP domains, and it is involved in various biological processes due to its structural properties.
Inhibitors that target WFDC16 are designed to bind to this protein and modulate its function through direct interaction. The binding of these inhibitors typically occurs at specific sites on the WFDC16 protein that are important for its activity, often involving the WAP domain itself. By binding to these sites, WFDC16 inhibitors can prevent the normal action of the protein, which may influence the biological pathways in which WFDC16 participates. The development and characterization of such inhibitors are driven by a detailed understanding of the protein's structure and the biochemical mechanisms by which it interacts with other molecules. Researchers employ a range of techniques, including crystallography, computational modeling, and mutagenesis studies, to identify potential inhibition sites and to design molecules that can effectively target WFDC16. The specificity and efficacy of WFDC16 inhibitors depend on the precise interaction between the inhibitor molecule and the protein's active or binding sites, which is a focal point in the study of this class of compounds.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a potent and selective inhibitor of mitogen-activated protein kinase kinase (MAPKK, also known as MEK). By inhibiting MEK, PD98059 indirectly reduces the activity of extracellular signal-regulated kinases (ERKs), which could lead to a downstream decrease in the functional activity of WFDC16 if it is regulated by the MAPK/ERK pathway. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a specific inhibitor of phosphoinositide 3-kinases (PI3K). By blocking PI3K activity, it prevents the activation of the Akt signaling pathway. If WFDC16 functionality is connected to the PI3K/Akt pathway, the inhibition of this pathway could result in decreased activity of WFDC16. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a pyridinyl imidazole compound that acts as a selective inhibitor of p38 MAP kinase. Inhibition of the p38 MAPK pathway can suppress the activity of downstream proteins that are regulated through this pathway, potentially leading to reduced activity of WFDC16 if it is a downstream target. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an anthrapyrazolone inhibitor that selectively targets c-Jun N-terminal kinase (JNK). It prevents the phosphorylation and activation of JNK, which may affect downstream targets, including WFDC16, if its activity is modulated through the JNK signaling pathway. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a steroidal furan derivative acting as a potent and irreversible inhibitor of PI3K. Similar to LY294002, it blocks the PI3K/Akt pathway, potentially leading to decreased activity of WFDC16 if it is influenced by this signaling pathway. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is a macrolide compound that inhibits the mechanistic target of rapamycin (mTOR), a key regulator of cell growth and proliferation. By inhibiting mTOR signaling, it may indirectly reduce the functional activity of WFDC16 if WFDC16 activity is linked to mTOR-mediated pathways. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK1/2, which blocks the activation of ERK1/2. Through this inhibition, U0126 could lead to decreased signaling through the MAPK/ERK pathway, potentially affecting the activity of WFDC16 if it is regulated by this pathway. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor that prevents the degradation of proteins marked for destruction by the ubiquitin-proteasome pathway. If WFDC16 is regulated by protein degradation mechanisms, inhibition by bortezomib could lead to altered WFDC16 activity levels. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a tyrosine kinase inhibitor with activity against Bcr-Abl and Src family kinases. By inhibiting these kinases, it could affect signaling pathways that regulate the activity of WFDC16, leading to its decreased functional activity. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib is a multi-kinase inhibitor targeting several receptor tyrosine kinases (RTKs). If WFDC16 is modulated through pathways downstream of these RTKs, sorafenib could lead to a reduction in WFDC16 activity by blocking these signaling cascades. | ||||||